These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor. Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272 [TBL] [Abstract][Full Text] [Related]
3. [Thoracic Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor. Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological characteristics and treatment outcomes of advanced SMARCA4-deficient thoracic tumors. Wang A; Jin Y; Cao Z; Lu L; Li Z Cancer Med; 2024 Jan; 13(1):e6809. PubMed ID: 38124509 [TBL] [Abstract][Full Text] [Related]
6. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor. Zhou P; Fu Y; Tang Y; Jiang L; Wang W PeerJ; 2024; 12():e16923. PubMed ID: 38374950 [TBL] [Abstract][Full Text] [Related]
7. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas. Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100 [TBL] [Abstract][Full Text] [Related]
8. Thoracic SMARCA4-Deficient Undifferentiated Tumors With Unusual Presentations: A Case Series. Helmink AJ; Alshomrani A; Lauer SR; Yuil-Valdes A Int J Surg Pathol; 2024 Aug; 32(5):992-998. PubMed ID: 37903457 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M Front Immunol; 2021; 12():799455. PubMed ID: 35069581 [TBL] [Abstract][Full Text] [Related]
10. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy. Zhou P; Fu Y; Tang Y; Jiang L; Wang W Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886 [TBL] [Abstract][Full Text] [Related]
11. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report. Takada K; Sugita S; Murase K; Kikuchi T; Oomori G; Ito R; Hayasaka N; Miyanishi K; Iyama S; Ikeda H; Kobune M; Emori M; Kato J; Hasegawa T Thorac Cancer; 2019 Dec; 10(12):2312-2315. PubMed ID: 31617320 [TBL] [Abstract][Full Text] [Related]
12. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report. Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345 [TBL] [Abstract][Full Text] [Related]
13. Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature. Mundada M; Mannan KA; Vasu D; Ahmed F; K S Turk Patoloji Derg; 2024; 40(2):128-133. PubMed ID: 38265099 [TBL] [Abstract][Full Text] [Related]
14. Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods. Shi M; Pang L; Zhou H; Mo S; Sheng J; Zhang Y; Liu J; Sun D; Gong L; Wang J; Zhuang W; Huang Y; Chen Z; Zhao Y; Li J; Huang Y; Yang Y; Fang W; Zhang L Lung Cancer; 2024 Jun; 192():107818. PubMed ID: 38763102 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572 [TBL] [Abstract][Full Text] [Related]
16. All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC. Rekhtman N Clin Cancer Res; 2024 May; 30(9):1708-1711. PubMed ID: 38416596 [TBL] [Abstract][Full Text] [Related]
17. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses. Perret R; Chalabreysse L; Watson S; Serre I; Garcia S; Forest F; Yvorel V; Pissaloux D; Thomas de Montpreville V; Masliah-Planchon J; Lantuejoul S; Brevet M; Blay JY; Coindre JM; Tirode F; Le Loarer F Am J Surg Pathol; 2019 Apr; 43(4):455-465. PubMed ID: 30451731 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of immune checkpoint inhibitors in SMARCA4-deficient and TP53 mutant undifferentiated lung cancer. Chen J; Zheng Q; Wang J; Zhang X; Lv Y Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494 [TBL] [Abstract][Full Text] [Related]
19. The Potential of Immunotherapy for SMARCA4-Deficient Undifferentiated Uterine Sarcoma (SDUS). Yao X; He Y; Xiao C; Zhou R; Zhao C; Wang W Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199375 [TBL] [Abstract][Full Text] [Related]
20. The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation. Li X; Tian S; Shi H; Ta N; Ni X; Bai C; Zhu Z; Chen Y; Shi D; Huang H; Chen L; Hu Z; Qu L; Fang Y; Bai C Cancer Gene Ther; 2024 May; 31(5):687-697. PubMed ID: 38347129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]